King's College Hospital
London, United Kingdom
NCT Number: NCT05140564
There is currently no effective intervention for type 1 diabetes and eating disorders. The main objective of STEADY Stage 2 is to test the feasibility of the newly developed STEADY intervention.
STEADY was co-designed by using Experience Based Co-Design methodology and other qualitative methods (focus groups, interviews).
These findings informed the development of a T1DM cognitive behaviour therapy (CBT) manual. The intervention will now be tested in a feasibility Randomised Controlled Trial (RCT) in adults with type 1 diabetes and eating disorders and compared with usual clinical care. If STEADY is feasible, this may provide an effective intervention for this population.
This study will take place at King's College London. Participants will remain in the study for 6 months, with a 12-month extended observation period. The study is expected to end in February 2023.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
London, United Kingdom
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
STEADY is a novel Cognitive Behavioural Therapy (CBT) based intervention for eating disorders in type 1 diabetes.
Time frame: 6 months
HbA1c measured in mmol/mol
King's College London
Other
Safe Management of People With Type 1 Diabetes and EAting Disorders studY - Phase II
Acronym: STEADY-II
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04741568
Autoimmune Diseases, Children, Only
Brighton, United Kingdom
View Trial DetailsNCT06236256
Autoimmune Diseases, Diabetes Mellitus
Ramat Gan, Israel
View Trial DetailsNCT07711275
Autoimmune Diseases, Diabetes Mellitus
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT03938324
Anemia, Anemia, Hemolytic
Durham, North Carolina, United States
View Trial Details